Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year
Status:
Withdrawn
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well lopinavir/ritonavir works in treating COVID-19 positive
patients with cancer and a weakened immune system (immune-suppression) in the last year and
have mild or moderate symptoms caused by COVID-19. Lopinavir/ritonavir may help to lessen or
prevent COVID-19 symptoms from getting worse in cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
National Cancer Institute (NCI) Oregon Health and Science University